Showing 1861-1870 of 3314 results for "".
- Orbis Launches AI-Led Diabetic Retinopathy Screening Project in Vietnamhttps://modernod.com/news/orbis-launches-ai-led-diabetic-retinopathy-screening-project-in-vietnam/2482401/Orbis has launched an AI-led diabetic retinopathy (DR) project in Vietnam, aiming to screen 72,000 people with diabetes over the next 3 years. The initiative focuses on providing AI-driven screenings, specialized training for screening teams, and enhancing community awareness of diabeti
- Lenz Therapeutics Submits NDA for LNZ100 Eye Drop for Presbyopiahttps://modernod.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/Lenz Therapeutics has submitted a new drug application (NDA) to the FDA for LNZ100, an investigational presbyopia eye drop. This aceclidine-based ophthalmic solution is designed to improve near vision in people with presbyopia. The NDA submission follows the successful completion o
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- EyeCare Partners Names New Members to Executive Leadership Teamhttps://modernod.com/news/eyecare-partners-names-new-members-to-executive-leadership-team/2482321/EyeCare Partners announced new additions and changes to its executive leadership team. Appointments and changes are: Andrew Hardesty has been promoted to the new role of Chief Program Officer, effective immediately. This role oversees and lea
- B+L Introduces INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/Bausch + Lomb has introduced 'INFUSE for Astigmatism' daily disposable contact lenses in the US. Engineered with a next-generation lens material infused with ProBalance Technology and the company’s proprietary OpticAlign design, Bausch + Lomb says INFUSE for
- Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/Bausch + Lomb announced the US launch of Zenlens Echo, a non-prosthetic, custom scleral contact lens. The Echo is designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative con
- LEP Biomedical Closes Pre-Seed Funding to Advance HyaGuard Platformhttps://modernod.com/news/lep-biomedical-closes-pre-seed-funding-to-advance-hyaguard-platform/2482243/LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Accordin
- Lenz Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialshttps://modernod.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/Lenz Therapeutics announced positive topline results from its phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In phase 3 safety and efficacy trials (CLARITY 1 and 2), our lead product candidate LNZ100 (1.75% ac
- OnPoint Vision Initiates Phase 1 Trial of AccuraSee Intraocular Pseudophakic Capsular Lens Magnifierhttps://modernod.com/news/onpoint-vision-initiates-phase-1-trial-of-accurasee-intraocular-pseudophakic-capsular-lens-magnifier/2482184/OnPoint Vision announced open enrollment of the phase 1 IDE clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing 6mm acrylic posterior chamber IOL. The IOPCL MAG is neu